The estimated Net Worth of Detlev Biniszkiewicz is at least $56 ezer dollars as of 3 January 2022. Detlev Biniszkiewicz owns over 3,500 units of iTeos Therapeutics stock worth over $55,965 and over the last 4 years Detlev sold ITOS stock worth over $0.
Detlev has made over 1 trades of the iTeos Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Detlev exercised 3,500 units of ITOS stock worth $66,500 on 3 January 2022.
The largest trade Detlev's ever made was exercising 3,500 units of iTeos Therapeutics stock on 3 January 2022 worth over $66,500. On average, Detlev trades about 875 units every 0 days since 2020. As of 3 January 2022 Detlev still owns at least 3,500 units of iTeos Therapeutics stock.
You can see the complete history of Detlev Biniszkiewicz stock trades at the bottom of the page.
Detlev's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol... és Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
iTeos Therapeutics executives and other stock owners filed with the SEC include: